Our Focus

T cells are the master regulators of the immune system

And they are at the heart of tissue damage in a number of autoimmune diseases. Autoreactive T cells have a role in breaking tolerance and directly drive inflammation and tissue destruction.

By modulating the activity of T cells , our targets can change how T cells activate, differentiate, migrate, and damage tissues.

Using our redosable ctLNP delivery system to selectively target T cells in vivo may open a broad indication space of T cell-driven autoimmune diseases.

A new delivery technology that selectively
modulates T cells in vivo with siRNA

Cell specific

Selective knockdown in pathogenic T cells , while avoiding other immune and hematologic cell types

Reaching undruggable targets

siRNA enables inhibition of targets with genetic precision, including those unreachable with small molecules or antibodies

Differentiated pharmacology

Selectivity and redosability of ctLNP-siRNA allows more predictable, tuneable target inhibition, driving wide therapeutic index

Pursuing high-value, poorly drugged or undruggable targets in autoimmune diseases

We’re focused on autoimmune targets that have been undruggable or poorly drugged selectively in T cells . We believe that the future of effective autoimmune disease therapy lies in achieving a powerful combination of broad therapeutic index and product safety.

We focus on targets that:

Powerful well-characterized target that has been difficult or impossible to drug selectively in T cells with existing modalities

Clear connection of the target driving autoimmune biology in high unmet need indications

Validated clinical pathway with an early opportunity to show efficacy and potential superiority vs standard of care

We plan to announce our lead target and indications in mid-2025 and anticipate filing our first IND in the second half of 2026.

It takes an exceptional team to fuel breakthrough science

We’re a collective of experts and industry leaders committed to changing what’s possible for patients living with T cell-driven autoimmune disease.